The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab
Carlo Pincelli, Eric Henninger, Florence Casset-SemanazVolume:
298
Language:
english
Pages:
10
DOI:
10.1007/s00403-006-0694-9
Date:
December, 2007
File:
PDF, 475 KB
english, 2007